Formulations of 5-fluorocytosine and uses thereof
AssigneeTocagen Inc.
InventorsHarry E. Gruber, Douglas J. Jolly, Kay Olmstead
Life of this patent
Estimating the term…
Abstract
The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.
Claims18
A gastro-retentive oral pharmaceutical composition comprising 5-fluorocytosine (5-FC), wherein the pharmaceutical composition is a monolithic solid tablet form comprising at least one hydrophilic matrix forming polymer of about 5 to 40 weight percent, hydroxymethyl cellulose (HPC) and microcrystalline cellulose (MCC) of about 5 to 30 weight percent, dicalcium phosphate of about 11 weight percent, magnesium stearate and opadry white and releases 5-FC into the upper gastrointestinal tract of a subject over a sustained period of time.
Dependencies are inferred from the claim text.